PRTA — Prothena Corporation plc Stock Price, Chart & AI Report

Positive Nov 12, 2025 • 14:24 UTC Benzinga • Vandana Singh

Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker

Novo Nordisk presented Phase 2 trial results for Coramitug, an antibody targeting transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The drug showed a statistically significant reduction in heart failure biomarker NT-proBNP and was well-tolerated.

NVO PRTA PFE ALNY heart failure biomarker clinical trial antibody

Sentiment note

Originally developed Coramitug and can earn up to $1.2 billion in milestone payments

Negative Aug 29, 2025 • 14:09 UTC Benzinga • Vandana Singh

FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's Therapy

The FDA now requires an additional MRI scan before the third Leqembi infusion to detect early signs of brain swelling (ARIA-E), a rare but potentially fatal side effect of the Alzheimer's treatment.

BIIB LLY PRTA FDA Alzheimer's Leqembi MRI safety guidelines

Sentiment note

Clinical trial results showed higher ARIA-E rates, making their drug PRX012 potentially less suitable for early symptomatic Alzheimer's patients

Negative Feb 17, 2025 • 23:10 UTC GlobeNewswire Inc. • N/A

Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm

Kuehn Law, a shareholder litigation law firm, is investigating potential self-dealing by officers and directors of Prothena Corporation PLC. Shareholders may be entitled to damages and corporate governance reforms.

PRTA shareholder litigation fiduciary duties self-dealing corporate governance

Sentiment note

The article indicates that Kuehn Law is investigating potential breaches of fiduciary duties by Prothena's officers and directors, which suggests potential wrongdoing or mismanagement within the company.

Positive Feb 13, 2025 • 18:00 UTC GlobeNewswire Inc. • Delveinsight

Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight

The article discusses the growing pipeline of alpha-synuclein inhibitors, a class of investigational therapies targeting the aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases. The pipeline includes over 20 active players and 22+ pipeline therapies, with several promising candidates in various stages of clinical trials.

ANVS ATHE DNLI HLBAY alpha-synuclein neurodegenerative diseases Parkinson's disease clinical trials

Sentiment note

Prothena Corporation is mentioned as one of the key companies working on alpha-synuclein inhibitors, suggesting their contribution to the advancement of this therapeutic area.

Neutral Dec 19, 2024 • 16:31 UTC Benzinga • Benzinga

Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits

Prothena's Parkinson's drug prasinezumab, partnered with Roche, missed the primary endpoint in a Phase 2b study, but showed potential clinical benefits in secondary analyses.

PRTA RHHBY Prothena Roche Parkinson's disease clinical trial

Sentiment note

The article reports that Prothena's Parkinson's drug prasinezumab missed the primary endpoint in a Phase 2b study, but showed potential clinical benefits in secondary analyses, indicating a mixed outcome.

Positive Oct 14, 2024 • 17:00 UTC GlobeNewswire Inc. • Delveinsight

Tau Inhibitors Clinical Trial Pipeline Analysis Demonstrates 25+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight

The rising incidence of Alzheimer's and other tau-related disorders is driving the demand for tau-targeting therapies. Innovative approaches, particularly small molecules that inhibit tau aggregation, are at the forefront of R&D. Increased funding is accelerating advancements in neurodegenerative disease treatments, positioning tau inhibitors as a key market driver.

IONS ATHE VYGR PRTA Tau inhibitors Alzheimer's disease neurodegenerative diseases clinical trials

Sentiment note

Prothena is one of the key companies working on developing tau inhibitors, indicating a promising pipeline in this area. The company also announced positive topline results from a clinical trial.

Unknown Jun 24, 2024 • 12:48 UTC Zacks Investment Research • Zacks Equity Research

Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last?

Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

PRTA ALEC

Unknown Jun 19, 2024 • 17:00 UTC Zacks Investment Research • Sanghamitra Saha

Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?

On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.

BIIB LLY PRTA IHE

Unknown Jun 14, 2024 • 15:21 UTC Zacks Investment Research • Zacks Equity Research

Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)

If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.

BIIB LLY PRTA SAVA

Unknown Jun 14, 2024 • 15:10 UTC Zacks Investment Research • Zacks Equity Research

The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)

Biogen, Eli Lilly's, Prothena and AC Immune are included in this Analyst Blog.

BIIB LLY PRTA ACIU

Unknown Jun 13, 2024 • 10:09 UTC Zacks Investment Research • Zacks Equity Research

The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune

Biogen, Eli Lilly's, Prothena and AC Immune are included in this Analyst Blog.

BIIB LLY PRTA ACIU

Unknown Jun 12, 2024 • 14:22 UTC Zacks Investment Research • Kinjel Shah

Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab

If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.

BIIB LLY PRTA ACIU